Janssen Pharmaceutica NV (Janssen) is a subsidiary of the global pharmaceutical, medical devices and consumer packaged goods manufacturer, Johnson & Johnson. The main research facilities in Europe are located in Beerse, Belgium, with research focused around the therapeutic areas of Neuroscience, Oncology, and Infectious Diseases. Janssen strives to eliminate disease through developing transformational medical solutions and making these accessible to people around the world. To achieve this, Janssen directs its efforts and resources on diseases where the unmet medical need is high, its internal capabilities strong, and the external science it can partner with compelling. With over 50 years of experience in pharmaceutical R&D, Janssen enjoys an international reputation for pharmaceutical innovation and quality. In 2010 Janssen launched the Discovery Data Integrity initiative (DDI) across the global Drug Discovery environment, setting up a global Quality Management System and Maintenance Program in the non-regulated space, with initial focus on internal preclinical data quality and subsequent expansion to also include data generated by external collaborators and service providers generating data on behalf of the company. As part of these activities, Janssen improved its data management processes and implemented internal guidelines, training an awareness campaigns, as well as a spot check program. Over the last years, Janssen gained increasing experience in collaborations with external partners to improve preclinical data quality processes. Neuroscience is one of Janssen’s key areas with a long and successful drug development history and several CNS drugs on the market, such as haloperidol, risperidone and paliperidone, methylphenidate, fentanyl and galantamine, the latter for the symptomatic treatment of Alzheimer’s disease. In fact, Alzheimer’s disease remains a focus area within Janssen Neuroscience Drug Discovery. Naturally, Janssen also has the internal safety and toxicology capabilities needed in support of drug development.